Vivos Therapeutics, Inc. (VVOS) Financial Ratios
7 years of historical data (2018–2024) · Healthcare · Medical - Devices
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
0.42
↓-96% vs avg
5yr avg: 9.95
30Y Low1.9·High36.9
ROE
↓
-266.3%
-10% vs avg
5yr avg: -242.6%
30Y Low-266%·High-96%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
VVOS Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Vivos Therapeutics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $5M | $22M | $15M | $9M | $48M | $108M | — | — |
| Enterprise Value | $737900 | $17M | $16M | $8M | $25M | $91M | — | — |
| P/E Ratio → | -0.30 | — | — | — | — | — | — | — |
| P/S Ratio | 0.36 | 1.43 | 1.10 | 0.58 | 2.83 | 8.24 | — | — |
| P/B Ratio | 0.42 | 2.71 | 36.91 | 1.93 | 1.87 | 6.36 | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
VVOS EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.12 | 1.12 | 0.51 | 1.50 | 6.94 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
VVOS Profitability
Margins and return-on-capital ratios measuring operating efficiency
Vivos Therapeutics, Inc. earns an operating margin of -74.3%. Operating margins have expanded from -156.2% to -74.3% over the past 3 years, signaling improving operational efficiency. A negative ROE of -266.3% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 60.0% | 60.0% | 59.9% | 62.5% | 74.6% | 79.7% | 76.0% | 71.5% |
| Operating Margin | -74.3% | -74.3% | -125.3% | -156.2% | -115.3% | -66.7% | -92.8% | -219.8% |
| Net Profit Margin | -74.1% | -74.1% | -98.4% | -148.8% | -120.2% | -92.3% | -94.4% | -225.3% |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| ROE | -266.3% | -266.3% | -521.2% | -157.2% | -95.6% | -172.6% | -1141.8% | -177.0% |
| ROA | -85.6% | -85.6% | -111.1% | -100.6% | -68.8% | -73.3% | -136.5% | -104.1% |
| ROIC | -422.2% | -422.2% | -582.0% | -549.2% | -929.3% | -4370.9% | -348.3% | -146.8% |
| ROCE | -162.5% | -162.5% | -334.3% | -151.3% | -89.1% | -109.1% | -469.6% | -137.9% |
VVOS Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $6M exceeds total debt of $2M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.19 | 0.19 | 4.85 | 0.50 | 0.06 | 0.08 | — | 0.14 |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.60 | 0.86 | -0.23 | -0.88 | -1.00 | — | -0.12 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | -1390.79 | -90.08 | -76.72 | -80.95 |
Net cash position: cash ($6M) exceeds total debt ($2M)
VVOS Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.50x means Vivos Therapeutics, Inc. can comfortably meet its short-term obligations, though there is limited excess liquidity. The current ratio has improved from 0.80x to 1.50x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.50 | 1.50 | 0.34 | 0.80 | 3.64 | 2.61 | 0.22 | 0.93 |
| Quick Ratio | 1.50 | 1.50 | 0.34 | 0.80 | 3.64 | 2.61 | 0.19 | 0.93 |
| Cash Ratio | 1.26 | 1.26 | 0.23 | 0.52 | 3.20 | 2.33 | 0.05 | 0.58 |
| Asset Turnover | — | 0.98 | 1.29 | 1.17 | 0.50 | 0.52 | 1.51 | 0.46 |
| Inventory Turnover | 10.37 | — | — | — | — | — | 10.37 | — |
| Days Sales Outstanding | — | 10.44 | 5.34 | 10.41 | 37.16 | 42.34 | 30.63 | 57.29 |
VVOS Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Vivos Therapeutics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 3.1% | 2.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 3.1% | 2.0% | — | — |
| Shares Outstanding | — | $5M | $1M | $920484 | $849320 | $728378 | $496427 | $461926 |
Peer Comparison
Compare VVOS with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 VVOSYou | $5M | -0.3 | — | — | 60.0% | -74.3% | -266.3% | -422.2% | — |
 ALGN | $12B | 29.8 | 13.9 | 24.6 | 68.3% | 15.3% | 10.4% | 15.4% | 0.1 |
 INVA | $2B | 6.9 | 8.1 | 9.9 | 72.3% | 38.5% | 29.1% | 14.2% | 1.3 |
 RMTI | $31M | -5.2 | — | — | 16.9% | -6.8% | -15.3% | -11.0% | — |
 DXCM | $24B | 29.1 | 20.6 | 21.8 | 60.0% | 19.6% | 34.5% | 18.7% | 1.2 |
 XRAY | $2B | -3.7 | 7.2 | 21.1 | 50.0% | 6.8% | -36.4% | 5.1% | 4.1 |
 HSIC | $8B | 21.6 | 10.9 | 14.1 | 29.1% | 5.7% | 8.3% | 7.1% | 3.4 |
 SRDX | $615M | -52.4 | 200.6 | — | 73.8% | -4.5% | -9.7% | -3.7% | 10.9 |
 MMSI | $4B | 29.3 | 13.1 | 17.2 | 48.7% | 12.2% | 8.7% | 7.2% | 2.8 |
 NVCR | $2B | -13.8 | — | — | 74.5% | -23.5% | -38.9% | -16.4% | — |
 ITGR | $3B | 30.4 | 13.1 | 28.8 | 23.1% | 11.3% | 6.1% | 5.4% | 4.2 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 7 years · Updated daily
See VVOS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs VVOS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare VVOS vs ALGN
Side-by-side business, growth, and profitability comparison vs Align Technology, Inc..
Start ComparisonVVOS — Frequently Asked Questions
Quick answers to the most common questions about buying VVOS stock.
What is Vivos Therapeutics, Inc.'s P/E ratio?
Vivos Therapeutics, Inc.'s current P/E ratio is -0.3x. This places it at the 50th percentile of its historical range.
What is Vivos Therapeutics, Inc.'s ROE?
Vivos Therapeutics, Inc.'s return on equity (ROE) is -266.3%. The historical average is -173.7%.
Is VVOS stock overvalued?
Based on historical data, Vivos Therapeutics, Inc. is trading at a P/E of -0.3x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Vivos Therapeutics, Inc.'s profit margins?
Vivos Therapeutics, Inc. has 60.0% gross margin and -74.3% operating margin.